AB0636 ASYMPTOMATIC HYPERURICEMIA IN INFLAMMATORY RHEUMATIC DISEASES
Authors: A. Fonturenko, R. Bashkinov, V. Mazurov, M. Petrova, O. Inamova, I. Gaydukova
Journal: Annals of the Rheumatic Diseases (2021)

Background: Uric acid (UA) is well-known biomarker of cardiovascular risk and inflammation. However, the data about interrelations between asymptomatic hyperuricemia (AHU) and rheumatic diseases (RD) are limited and contradictory [1]. Objectives: to identify the occurrence of AHU in pts with different RD and to evaluate the interrelations between the AHU and clinical features of the RD. Methods: The study included data from 822 pts with AHU and RD involved in the Saint-Petersburg Register of Pts with AHU in period from the 01jan2000 to the 01apr2020. The AHU was defined as the serum level of uric acid (UA) that exceeded 360 μmol/l without signs of gouty arthritis. Pts with the secondary reasons of AHU (an oncologic diseases, late stages of chronic kidney disease, ets), and inflammatory diseases another than RD were excluded from the study. Patient’s demographical characteristics, duration of AHU, level of UA, activity of RD, ESR, CRP, urate-lowering therapy (ULT) were analyzed. The study was approved by local ethic committee. Statistics was performed with SPSS17. Results: Characteristics of the Patients with the RD and AHU are present in Table 1. The duration of AHU in pts with the RD was 3.4±3.4 [0.08-18] years, mean duration of follow-up 2.7±4.0 years, mean number of visits during the period of follow-up was 3,2 [min 1; max 7], ESR 26.0±14.1 mm / h, CRP 19.6±21.0 mg/l. Table 1. Characteristics of the Patients with the Rheumatic diseases and asymptomatic hyperuricemia. Age, years (Mean±SD) Male, %** Serum UA, μmol/l (Mean±SD) Normalization of UA during the follow-up, n (%) RD, n=822 56.7±14.5 40.27 493.3±98.5 242 (29.44) ## RA, n=329 64.2±12.1 3.74 504.8±107.5 # 99 (30.09) ## PsA, n= 149 56.6±12.9 53.69 531.5±94.9 # 32 (21.48) ## SpA, n= 107 45.6±15.1* 33.43 520.8±86.5 # 18 (16.82) ## SLE, n=137 50.3±14.1* 20.44 451.6±91.4 57 (41.61) SSc, n= 57 61.0±12.4 22.81 456.2±99.5 20 (35.09) SD, n= 43 62.0±10.7 16.28 442.4±107.5 16 (37.21) RD – rheumatic disease; RA –– rheumatoid arthritis; PsA –– psoriatic arthritis; SpA –– spondyloarthritis; SLE –– systemic lupus erythematosus; SSc –– systemic sclerosis; SD –– Sjogren’s disease; * –– p&lt;0.001 for the differences with RD, RA, PsA, SSc, SD; ** –– p &lt; 0.01 for all intergroup differences; # –– p &lt; 0.01 for the differences with RD, RA, SSc, SD; ## –– p &lt; 0.01 for the differences with RA, SSc, SD. Were revealed the interrelations between the level of UA and ESR (Spearmen’s R=0.1, p=0.01), and UA and CRP (Spearmen’s R =0.12, p=0.001). The level of UA in male pts was 507.0 [361-940], in female pts 450.0 [361-1010] μmol /l (p&lt;0.0001), in SLE pts with elevated anti-nuclear factor (ANF) UA was 429 [361-940] and with normal 494 [361-973] (p&lt;0.0001). In pts with high and low RD activity UA was 490 [361-940] and 454 [363-1010]) μmol /l respectively, (p&lt;0.0001). The higher UA level was found in any RD as compared with UA in low activity of the same RD (p&lt;0.0001 for all the differences). Normalization of UA was found in 243 (29.6 %) pts, lack of normalization of UA in 434 (52.8 %) of cases, n = 677, Table 1. ULT received 219 (26.6 %) pts. Normalization of UA without ULT was registered in 16 (1.9 %) of the pts. Conclusion: UA level is higher and normalize less often in patients with SpA and PsA as compered with RA, SLA, SSc and SD pts. In any of analyzed rheumatic diseases the level of UA is higher in male pts and in pts with high disease activity. References: [1]K.Bosmansky, M. Ondrasik. Ter Arkh.1987;59(4):22-5. Disclosure of Interests: None declared.